Adriana R T Anastasio1, Aparecida Y Yamamoto2, Eduardo T Massuda3, Alessandra K S Manfredi4, Juliana M S Cavalcante4, Bruno C P Lopes3, Davi C Aragon2, Suresh Boppana5, Karen B Fowler5, William J Britt5, Marisa M Mussi-Pinhata2. 1. Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil. anastasi@fmrp.usp.br. 2. Department of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil. 3. Department of Ophthalmology, Otorhinolaryngology, and Head and Neck Surgery, Ribeirão Preto Medical School-University of São Paulo, São Paulo, Brazil. 4. Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil. 5. Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Abstract
OBJECTIVES: To determine the incidence and risk factors of hearing loss (HL) in Brazilian neonates. STUDY DESIGN: 11,900 neonates were screened for hearing and congenital CMV (cCMV). Low and high-risk babies who did not pass their hearing screening and infants with cCMV were scheduled for a diagnostic audiologic evaluation. RESULTS: The incidence of HL was 2 per 1000 live-born infants (95% CI: 1-3). HL was higher in high-risk neonates than in low risk babies (18.6 vs. 0.3/1000 live births, respectively). Among infants exposed to isolated risk factors, association of HL with craniofacial abnormalities/syndromes (RR = 24.47; 95% CI: 5.9-100.9) and cCMV (RR = 9.54; 95% CI: 3.3-27.7) were observed. HL was 20 to 100-fold more likely in neonates exposed to ototoxic drugs in combination with cCMV or craniofacial/congenital anomalies. CONCLUSIONS: Strategies for the prevention of cCMV and exposure to ototoxic drugs may decrease the incidence of HL in this population.
OBJECTIVES: To determine the incidence and risk factors of hearing loss (HL) in Brazilian neonates. STUDY DESIGN: 11,900 neonates were screened for hearing and congenital CMV (cCMV). Low and high-risk babies who did not pass their hearing screening and infants with cCMV were scheduled for a diagnostic audiologic evaluation. RESULTS: The incidence of HL was 2 per 1000 live-born infants (95% CI: 1-3). HL was higher in high-risk neonates than in low risk babies (18.6 vs. 0.3/1000 live births, respectively). Among infants exposed to isolated risk factors, association of HL with craniofacial abnormalities/syndromes (RR = 24.47; 95% CI: 5.9-100.9) and cCMV (RR = 9.54; 95% CI: 3.3-27.7) were observed. HL was 20 to 100-fold more likely in neonates exposed to ototoxic drugs in combination with cCMV or craniofacial/congenital anomalies. CONCLUSIONS: Strategies for the prevention of cCMV and exposure to ototoxic drugs may decrease the incidence of HL in this population.
Authors: Aparecida Y Yamamoto; Adriana R T Anastasio; Eduardo T Massuda; Myriam L Isaac; Alessandra K S Manfredi; Juliana M S Cavalcante; Adriana Carnevale-Silva; Karen B Fowler; Suresh B Boppana; William J Britt; Marisa M Mussi-Pinhata Journal: Clin Infect Dis Date: 2020-03-17 Impact factor: 9.079